

***Merger Plan with Topotarget:***

***BioAlliance Pharma has received pre-approval for the secondary listing of the shares of the merged company on NASDAQ OMX Copenhagen***

**Paris, June 20, 2014** - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, today announces that it has received a pre-approval from NASDAQ OMX Copenhagen for the secondary listing and admission to trading on NASDAQ OMX Copenhagen of the shares of BioAlliance Pharma SA, subject to completion of the merger of Topotarget and BioAlliance Pharma, resulting in the creation of Onxeo.

Onxeo aims at becoming a global leader on the fast-growing market of orphan oncology drugs. It will hold a complementary portfolio of advanced programs targeting severe pathologies for which there is an unmet medical need. Onxeo will offer reinforced market attractiveness, notably towards specialized international investors, through a more important critical mass, a European scale and a high added value product portfolio.

The merger will be submitted to the vote of Topotarget and BioAlliance Pharma shareholders, respectively on June 27, 2014 and on June 30, 2014.

Once the merger is completed and subject to the renewed approval by NASDAQ OMX, the shares of Onxeo will be listed on both Euronext Paris and NASDAQ OMX Copenhagen stock markets in order to allow Topotarget shareholders, who will become Onxeo shareholders, to remain able to trade their Onxeo shares on the Danish stock market. The shares of the merged company will be identified with the ticker "ONXEO" on Euronext Paris and NASDAQ OMX Copenhagen stock markets.

**About BioAlliance Pharma**

Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

**Orphan Oncology products**

Livatag<sup>®</sup> (Doxorubicin Transdrug<sup>™</sup>) (primary liver cancer): Phase III on going  
Validive<sup>®</sup> (Clonidine Lauriad<sup>®</sup>) (mucositis): Phase II on going

AMEP<sup>®</sup>/Synfoldin (invasive melanoma): Clinical and Preclinical Phase

**BioAlliance Pharma has announced a merger plan with the Danish listed company Topotarget on May 21, 2014.**

For more information, visit the BioAlliance Pharma web site at [www.bioalliancepharma.com](http://www.bioalliancepharma.com)

***Disclaimer***

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website ([www.bioalliancepharma.com](http://www.bioalliancepharma.com)).*

**BioAlliance Pharma SA**

Judith Greciet, CEO  
[judith.greciet@bioalliancepharma.com](mailto:judith.greciet@bioalliancepharma.com)  
Nicolas Fellmann, CFO  
[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)  
Tel.: +33 1 45 58 76 00

**ALIZE RP**

Caroline Carmagnol  
+33 6 64 18 99 59  
[bap@alizerp.com](mailto:bap@alizerp.com)